Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

58 results about "Orexin receptor" patented technology

The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin. There are two variants, OX₁ and OX₂, each encoded by a different gene (HCRTR1, HCRTR2).

Pyrrolidine orexin receptor agonists

ActiveUS12331018B2Nervous disorderOrganic chemistryDiseaseOrexin Receptor Agonists
The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Owner:MERCK SHARP & DOHME LLC

Orexin receptor modulator and preparation method and application thereof

The invention discloses an orexin receptor modulator as well as a preparation method and application thereof, and particularly discloses an orexin receptor antagonist shown in the following formula. The orexin receptor antagonist provided by the invention can be used for treating nervous system related diseases. # imgabs0 #
Owner:CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD

Deuterated benzamide diazepine compounds, methods of making and uses thereof

PendingCN122464875ADiseaseSide effect
The application discloses a kind of deuterated benzamide diazepine compounds and preparation method and purposes thereof, and structure is as shown in general formula I.The compound is used as selective OX2R antagonist, and shows good activity, selectivity, brain exposure, brain blood ratio (the ratio of drug concentration in brain and drug concentration in blood, is called B / P), little toxic side effect, moderate half-life effect etc..It can be used for preventing, treating and / or reducing the disease related to orexin receptor.General formula I
Owner:NINGBO INST OF MARINE MEDICINE PEKING UNIV

Orexin receptor modulator, and preparation method therefor and use thereof

Disclosed in the present invention are an orexin receptor modulator, and a preparation method therefor and the use thereof, and specifically disclosed is an orexin receptor antagonist as shown in the following formula. The orexin receptor antagonist provided by the present invention can be used for treating diseases related to the nervous system.
Owner:CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD

Application of compound in preparation of medicine for treating insomnia and / or anxiety disorder

The invention belongs to the technical field of nerve drugs, and particularly relates to application of an orexin receptor 1 antagonist and / or an orexin receptor 2 antagonist in preparation of drugs for treating insomnia or anxiety, and the compound is a compound and salt shown in the following structure. In in-vivo experiments, the traditional Chinese medicine composition shows a more excellent anti-insomnia effect and shows a good anti-anxiety effect. In addition, the structure also has better stability and pharmacokinetic characteristics, such as higher exposure and half-life period.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and their use as orexin receptor agonists for treating or preventing neurological disorders - Patent Application 20070122993

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.
Owner:AEXON LABS INC

Orexin receptor agonists

PCT designated stageWO2025252662A1Hormone peptidesPeptide/protein ingredientsOrexin Receptor AgonistsPharmaceutical drug
The present invention relates to potent hOX1R / hOX2R agonists, as well as their use as a medicament, in particular for the treatment of narcolepsy. In particular, the present invention relates to potent hOX1R / hOX2R agonists, with prolonged half-life and good physiochemical properties.
Owner:GUBRA APS

Bicycloamine carboxamide derivative

The present invention relates to a compound of formula (1) or a pharmaceutically acceptable salt thereof with therapeutic and prophylactic effects for a disease associated with orexin receptor type 2, specifically, a disease such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, wherein R1 and R2 are each independently hydrogen atom, etc.; R3 and R4 are each independently hydrogen atom, etc.; R5 is optionally-substituted C1-4 alkyl; -L1-ring G is -ring G, -CH2-ring G, etc.; R6 is each independently hydrogen atom, etc.; n is an integer of 1 or 2; ring G is optionally-substituted C6-10 aromatic carbocyclyl group, etc.; A1 is oxygen atom, etc.; A2 is oxygen atom, etc.; j, k, 1, and m are each independently an interger of 0, 1, or 2; dashed bond is single bond or double bond; X is -CR7-, etc.; R7 is hydrogen atom, etc.; and ring E is formula (1a-1), (1a-2), or (1a-3).
Owner:SUMITOMO PHARMA CO LTD

Macrocyclic urea orexin receptor agonists

ActiveCN116600803BOrganic active ingredientsNervous disorderDiseaseOrexin Receptor Agonists
The present invention relates to macrocyclic urea compounds that are orexin receptor agonists. The present invention also relates to the use of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases involving the orexin receptors. The present invention also relates to compositions containing these compounds. The present invention also relates to the use of these compositions in the potential prevention or treatment of such diseases involving the orexin receptors.
Owner:默沙东有限责任公司

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
Owner:JANSSEN PHARMA NV

Substituted pyrazole and imidazole compositions as orexin receptor antagonists, methods of treating neurological and psychiatric disorders

The present disclosure relates to substituted imidazole and pyrazole ring derivatives of compounds that are orexin receptor antagonists that are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which or involving orexin receptors. The disclosure also relates to pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions in the prevention or treatment of diseases in which orexin receptors are involved.
Owner:HAGER BIOSCIENCES LLC

Screening method of active ingredients of anti-insomnia traditional Chinese medicine composition

The invention provides a method for screening active ingredients of an anti-insomnia traditional Chinese medicine composition. Comprising the following steps: 1, establishing a reversible adsorption peptide tag target protein expression system; step 2, purification and reversible fixation of reversible adsorption peptide tag target protein; 3, investigating retention behaviors of the four specific ligands on a target egg white chromatographic column; 4, screening active ingredients of the targeted anti-insomnia traditional Chinese medicine composition through cortex albiziae-tuber fleeceflower stem. Silica gel reversible adsorption peptide is introduced to the tail end of an insomnia target orexin receptor to serve as a protein tag, unmodified macroporous silica gel serves as a matrix, so that capture and fixation of the orexin receptor in a complex system are achieved, and active ingredients of the target orexin receptor with a cortex albiziae-tuber fleeceflower stem drug pair as a core drug flavor are obtained through screening; the anti-insomnia effect of the traditional Chinese medicine composition is evaluated by using an insomnia mouse model, so that a reliable method is provided for screening active ingredients of the anti-insomnia traditional Chinese medicine, and a reliable traditional Chinese medicine composition is provided for treating insomnia.
Owner:NORTHWEST UNIV

Deuterated amide compound as well as preparation method and application thereof

The invention discloses a deuterated amide compound and a preparation method and application thereof, and belongs to the technical field of medicines, deuterated amides shown in the formula I or pharmaceutically acceptable salts thereof have orexin receptor antagonism, and can be used for preparing medicines for treating sleep disorders such as insomnia. Compared with the commercially available drugs, the deuterated amide compound provided by the invention has better pharmacokinetic characteristics. And more choices are provided for clinical treatment of sleep disorder diseases. # imgabs0 #
Owner:SHENYANG PHARMA UNIV

Improved synthetic process for preparing (2H-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators

The present invention relates to an improved synthetic process for the preparation of (2H-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators. The present invention describes a process for the preparation of (((3aR, 6aS)-5-(4, 6-dimethylpyrimidin-2-yl) hexahydropyrrolo [3, 4-c] pyrrol-2 (1H)-yl) (2-fluoro-6-(2H-1, 2, 3-triazol-2-yl) phenyl) ketone # imgabs0 #, which can be used in commercial manufacturing. The compounds are orexin receptor modulators and are useful in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by orexin activity, such as insomnia and depression.
Owner:JANSSEN PHARMA NV

Dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives and their use as orexin receptor agonists for treatment or prophylaxis of nervous system diseases

The present invention relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives for use in the prevention or treatment of neurological, psychiatric, sleep disorders and diseases, advantageously in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The invention also relates to pharmaceutical compositions comprising these compounds, their use for the prevention and / or treatment of nervous system disorders and diseases. The invention also relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives, and to the use of these compounds as medicaments.
Owner:AIXUN LABORATORIES CO LTD

Composition comprising probiotic bacteria and use thereof for the treatment of insomnia

PendingCN122145584Asuppress overactivationImprove insomnia symptomsNervous disorderPeptide/protein ingredientsProbiotic bacteriaOrexin Receptor Antagonists
The present application provides a composition comprising probiotics and its use for treating insomnia. Further, the present application also provides a dual orexin receptor antagonist polypeptide O-59 polypeptide, which can inhibit the over-activation of the orexin system by antagonizing the orexin 1 receptor (OX1R) and the orexin 2 receptor (OX2R), thereby improving sleep. After the polypeptide is combined with the probiotic composition, the insomnia symptoms of the insomnia mice can be significantly improved, and the application prospect is good.
Owner:GUANGZHOU NOSAI PRECISION MEDICINE BIOTECHNOLOGY CO LTD

Orexin receptor 2 (OX2R) agonist for use in narcolepsy type 1 (NT1)

PCT designated stageWO2025229584A2Nervous disorderAmide active ingredientsNocturnal blood pressureBlood pressure
Disclosed herein are methods, uses and composition for treating narcolepsy with cataplexy (narcolepsy type 1 or NT1), blunted nocturnal blood pressure dip in a subject having narcolepsy type 1 or cognitive impairment in a subject having narcolepsy type 1, by administering an orexin receptor 2 agonist to the subject at one or more daily dosages.
Owner:TAKEDA PHARMA CO LTD +14

CYCLOAKYLUREA DERIVATIVE

The present invention relates to a medicament for the treatment or prevention of a disease related to the orexin receptor, especially the orexin receptor type 2, comprising a novel compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient; more specifically, the present invention relates to a medicament for the treatment or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
Owner:SUMITOMO PHARMA CO LTD

Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

The present invention is directed to substituted Pyrazole and Imidazole derivatives of compounds that are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved or implicated, including but not limited to:The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Owner:HAGER BIOSCIENCES LLC

Imidazolo derivatives, compositions and methods as orexin antagonists

This disclosure is directed to substituted Imidazolo[2,1-b]oxazole, Imidazolo[2,1-b]thiazole, Imidazolo[2,1-b]oxadiazole, Imidazolo[2,1-b]oxadiathiazole derivatives of compounds that are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved or implicated. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Owner:HAGER BIOSCIENCES LLC

Cyclic olefin derivative as orexin receptor agonist, and composition and use thereof

PCT designated stageWO2026017183A1Organic active ingredientsOrganic chemistryDiseaseLethargy
A cyclic olefin derivative having an orexin 2 receptor (OX2R) agonistic activity. In particular, the present invention relates to a compound as represented by general formula (I), a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable salts of the stereoisomer and tautomer. The present invention also relates to a pharmaceutical composition containing the compound, a preparation method therefor, and the use thereof as an orexin 2 receptor (OX2R) agonist for preventing or treating diseases related to the agonistic effect of an orexin 2 receptor (OX2R), such as narcolepsy, lethargy, sleep apnea, anesthesia recovery or respiratory inhibition improvement. Each substituent in general formula (I) is the same as that defined in the description.
Owner:NHWA PHARMA CORPORATION

Halo-substituted piperidines as orexin receptor modulators

InactiveUS20240400550A1Nervous disorderOrganic chemistrySeasonal Affective DisordersPharmaceutical Substances
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Owner:NIUVERA BIO INC